We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Results from the trial were published in The New England Journal of Medicine.

chronic spontaneous urticaria (CSU), and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.

Approximately one in five individuals with COPD experience social isolation, twice the rate of older adults overall. Elevated rates of isolation may be the result of disease features such as ...

The Food and Drug Administration in June approved Verona's lead product, Ohtuvayre, as a maintenance treatment for chronic obstructive pulmonary disease, or COPD, in adult patients. Verona in the ...